NQO1 and familial pancreatic carcinoma: This compound, administered to pancreatic cancer patients, limited the MDSC-mediated immune suppression by inducing the upregulation of several antioxidant genes including NAD(P)H, quinone oxidoreductase 1 (NQO1), thioredoxin, catalase, superoxide dismutase, and heme oxygenase, while it did not affect the frequency of circulating MDSCs [35].